Risks and Liabilities of Delayed Diagnosis During COVID-19

Risks and Liabilities of Delayed Diagnosis During COVID-19

The Physician-Patient Alliance for Health & Safety (PPAHS) is pleased to announce that it will be moderating a panel discussion on the risks and liabilities of delayed diagnosis during COVID-19 at the upcoming Crittenden Medical Insurance Conference to be held virtually from April 13-14, 2021. If you would like to attend the Conference, please register here.

At the Crittenden Conference, Michael Wong, JD (Executive Director, PPAHS) will present findings from the survey of PPAHS’s respiratory clinicians conducted online from September 10-15, 2020. This survey found that a significant majority of clinicians were not recommending lung function testing during COVID-19 because of safety concerns. As well, he will discuss the risks and liabilities of delayed diagnosis during COVID-19.

Presenting with Mr. Wong on April 13, 2021, will be:

  • Naresh M. Punjabi, MD, Ph.D. – Dr. Punjabi is the Mary Jane and Lino Sertel Professor of Pulmonary Diseases, in the Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL. He is an adjunct Professor of Medicine at the Johns Hopkins School of Medicine. He is the Chief of Pulmonary, Critical Care and Sleep Medicine at the University of Miami Health System and the Miami VA hospital. He has over 200 peer-reviewed manuscripts, book chapters, and editorials and serves as editor-in-chief for Sleep, the journal from the American Academy of Sleep Medicine. Dr. Punjabi’s academic focus has examined mortality associated with sleep disorders, as well as the epidemiologic incidence of metabolic, heart, and other acute and chronic diseases in those with sleep and breathing syndromes.
  • Jason P. Kirkness, Ph.D. (Medicine), ATSF, has 20 years of training and experience in Pulmonary Physiology and Sleep Medicine. He was previously Assistant Professor of Medicine at Johns Hopkins School of Medicine in Baltimore where his areas of investigation were novel technology, biological instrumentation, diagnostics, and therapies for chronic diseases. He has received research funding from the National Institutes of Health, National Science Foundation, and the American Heart Foundation among others. He is an active long-standing and contributing member of the American Thoracic Society, CHEST, and SCCM, committee member of the ATS Drug Device Discovery and Development Committee. He has authored more than 70 peer-reviewed publications, book chapters, and editorials in respiratory medicine.

The panel will be discussing:

  • The results of the clinical survey about the administration of lung function testing during COVID-19.
  • The key reasons why lung function testing has not been performed during COVID-19.
  • The risks and liabilities of delaying, rescheduling, or canceling diagnostics lung function testing.
  • Technologies that may be used to measure lung dynamics and function that are outside of the normal for traditional PFT testing (such as spirometry)

For more information on the Crittenden Medical Insurance Conference and to register, please click here.

Leave a Comment, if You Care About Patient Safety